Most advanced BRS technology today!
Redefining the field, with
DES-like performance in a scaffold.
The world’s first and only sub-100 micron BRS with 9-month safety and performance evidence from a clinical study
Amaranth latest generation BRS at 85 μm
Planned clinical trials Q3/Q4 2019
Interim analysis indication of long term safety profile as demonstrated by a scaffold thrombosis rate of 0%:
APTITUDE® (115 μm) at 24 months
MAGNITUDE® (98 μm) at 18 months
Attend this ground-breaking symposium and learn about how Amaranth is establishing a new gold standard in vascular intervention.
The future of bioresorbable coronary scaffolds is here: the thin-walled high mechanical performance Amaranth Medical BRS programme.
Date: Wednesday, 23 May 2018
Room: 242A / Level 2, Palais des Congrès
Time: 13:30 - 14:30
Antonio Colombo, MD
Ospedale San Raffaele
Gregg W. Stone, MD
Columbia University Medical Center
13:35 Amaranth Medical BRS technology: current clinical scaffolds and experimental insights from the world’s thinnest (85 µm) BRS
Juan F. Granada
13:52 Foundational platform: FORTITUDE® 150 µm BRS 2- and 3-year clinical update
14:09 Advanced technology platforms: APTITUDE® 115 µm and MAGNITUDE® 98 µm BRS 9-month clinical updates
14:26 Session evaluation and key learnings
Gregg W. Stone
Pace-setting Technology Continues to
Demonstrate Safety and Viability of BRS